Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
GMAB Genmab
- Stocks
- Healthcare
- NASDAQ: GMAB
Price (delayed)
$19.88
Market cap
$13.16B
P/E Ratio
11.49
Dividend/share
N/A
EPS
$1.73
Enterprise value
$11.67B
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with
Highlights
GMAB's price to earnings (P/E) is 69% lower than its 5-year quarterly average of 37.3 and 32% lower than its last 4 quarters average of 17.0
The EPS has grown by 47% YoY
The quick ratio has dropped by 57% year-on-year but it is up by 2.1% since the previous quarter
The gross margin is down by 2.7% year-on-year
Key stats
What are the main financial stats of GMAB
Market
Valuations
Earnings
Shares outstanding
661.97M
Market cap
$13.16B
Enterprise value
$11.67B
Price to earnings (P/E)
11.49
Price to book (P/B)
2.48
Price to sales (P/S)
4.18
EV/EBIT
7.32
EV/EBITDA
N/A
EV/Sales
3.71
Revenue
$3.15B
Gross profit
$2.99B
Operating income
$1.01B
Net income
$1.11B
EBIT
$1.59B
EBITDA
N/A
Free cash flow
$1.09B
Per share
Balance sheet
Liquidity
EPS
$1.73
EPS diluted
$1.72
Free cash flow per share
$1.65
Book value per share
$8
Revenue per share
$4.76
TBVPS
$6.76
Total assets
$6.59B
Total liabilities
$1.29B
Debt
$129M
Equity
$5.3B
Working capital
$3.28B
Debt to equity
0.02
Current ratio
5.34
Quick ratio
5.33
Net debt/EBITDA
N/A
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
95.1%
Net margin
35.2%
Operating margin
32.2%
Return on assets
18.5%
Return on equity
23%
Return on invested capital
70.2%
Return on capital employed
27.3%
Return on sales
50.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GMAB stock price
How has the Genmab stock price performed over time
Intraday
1.17%
1 week
2.69%
1 month
1.69%
1 year
-32.95%
YTD
-4.74%
QTD
1.53%
Financial performance
How have Genmab's revenue and profit performed over time
Revenue
$3.15B
Gross profit
$2.99B
Operating income
$1.01B
Net income
$1.11B
Gross margin
95.1%
Net margin
35.2%
The net income has grown by 44% YoY
The operating income is up by 26% YoY and by 8% from the previous quarter
Genmab's revenue has increased by 25% YoY and by 4.5% QoQ
The company's gross profit rose by 22% YoY and by 4.1% QoQ
Price vs fundamentals
How does GMAB's price correlate with its fundamentals
Growth
What is Genmab's growth rate over time
Valuation
What is Genmab stock price valuation
P/E
11.49
P/B
2.48
P/S
4.18
EV/EBIT
7.32
EV/EBITDA
N/A
EV/Sales
3.71
GMAB's price to earnings (P/E) is 69% lower than its 5-year quarterly average of 37.3 and 32% lower than its last 4 quarters average of 17.0
The EPS has grown by 47% YoY
The P/B is 62% below the 5-year quarterly average of 6.5 and 20% below the last 4 quarters average of 3.1
The equity has grown by 16% YoY and by 3.1% from the previous quarter
The P/S is 69% below the 5-year quarterly average of 13.4 and 20% below the last 4 quarters average of 5.2
Genmab's revenue has increased by 25% YoY and by 4.5% QoQ
Efficiency
How efficient is Genmab business performance
Genmab's return on invested capital has surged by 60% YoY and by 9% QoQ
Genmab's ROE has increased by 29% YoY but it has decreased by 3.4% from the previous quarter
The ROA has grown by 17% YoY but it has contracted by 5% from the previous quarter
The ROS has grown by 7% YoY but it has contracted by 2.3% from the previous quarter
Dividends
What is GMAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GMAB.
Financial health
How did Genmab financials performed over time
The total liabilities has soared by 120% YoY
The current ratio has shrunk by 57% YoY
Genmab's debt is 98% less than its equity
GMAB's debt to equity is down by 33% since the previous quarter and by 33% year-on-year
The equity has grown by 16% YoY and by 3.1% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.